Global Blood Therapeutics (GBT) Received its Third Buy in a Row
After Cantor Fitzgerald and H.C. Wainwright gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics today. The company’s shares opened today at $43.50.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 14.3% and a 55.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Audentes Therapeutics, and Krystal Biotech Inc.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $84.56.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $26.10. Currently, Global Blood Therapeutics has an average volume of 1.3M.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.